Kindred Bio 10-K/A
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________________
FORM 10-K/A
(Amendment No. 1)
______________________
|
| |
x
| ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| For the fiscal year ended December 31, 2013 |
| |
o
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| For the transition period from _____ to ______ |
Commission file number: 001-36225
KINDRED BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
|
| | |
Delaware | | 46-1160142 |
(State or other jurisdiction of
incorporation or organization) | | (I.R.S. Employer
Identification Number) |
|
1499 Bayshore Highway, Suite 226 Burlingame, California 94010 | |
| (Address of principal executive offices) | |
| (650) 701-7901 | |
| Registrant’s telephone number: | |
Securities registered under Section 12(b) of the Act: Common Stock, $0.0001 par value.
Securities registered under Section 12(g) of the Act: None.
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No þ
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No þ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and, (2) has been subject to such filing requirements for the past 90 days.
Yes þ No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes þ No o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein and, will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. þ
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
|
| | | | | |
Large accelerated filer o | Accelerated filer o | Non-accelerated filer þ | Smaller reporting company o |
| | (Do not check if a smaller reporting company) | |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
Yes o No þ
The registrant completed the initial public offering of its common stock on December 12, 2013. Accordingly, there was no public market for the registrant’s common stock as of June 30, 2013, the last business day of the registrant’s most recently completed second fiscal quarter.
The outstanding number of shares of common stock as of March 10, 2014 was 16,227,120.
Documents incorporated by reference: Certain portions of the registrant’s Proxy Statement for the 2014 annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than 120 days after the close of the registrant’s fiscal year are incorporated by reference under Part III of this Form 10-K.
Explanatory Note
We are filing this Amendment No. 1 on Form 10-K/A (this “Amendment”) to our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, as filed with the Securities and Exchange Commission on March 14, 2014 (the “Form 10-K”), solely for the purpose of correcting a typographical error on page 4 under the heading “Advance CereKin, AtoKin, SentiKin and our other product candidates through development and regulatory approval” relating to the timing of potential marketing approvals for our first product candidates. The third sentence under this heading is corrected as as follows:
“If these trials and other development activities are successful, we expect to submit NADAs for CereKin starting in mid-2014, and for AtoKin and SentiKin in late 2014, with potential marketing approvals for the first of these products starting in mid-2015.”
No other sections of the Form 10-K are affected by this Amendment. This Amendment should be read in conjunction with the Form 10-K and the registrant’s other filings with the Securities and Exchange Commission. Except as described above, no other changes have been made in this Amendment to modify or update the other disclosures presented in the Form 10-K.
SIGNATURES
In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
| | |
| KINDRED BIOSCIENCES, INC. |
| | |
Date: March 17, 2014 | By: | /s/ Richard Chin, M.D. |
| | Richard Chin, M.D. |
| | President and Chief Executive Officer |